Flagging the varied well being issues surrounding the Covid anti-viral drug Molnupiravir, ICMR’s Dr Balram Bhargava mentioned that Merck’s coronavirus capsule has not been added to the nationwide therapy protocol resulting from some ‘main security issues.’
Bhargava, the pinnacle of the state-run Indian Council of Medical Analysis, raised the problem at a press briefing on Wednesday. “The US accredited Molnupiravir based mostly on 1,433 sufferers with a 3% discount in serious-moderate Covid illness. The drug may cause teratogenicity, mutagenicity and can even trigger cartilage harm. It may be damaging to muscle tissues as nicely,” he added. If a affected person consumes Molnupiravir, they might want to use a contraceptive for 3 months, each female and male because the little one born might be affected, he added.
With this, he mentioned that the drug has not been included within the nationwide job pressure therapy and that the World Well being Organisation and the UK haven’t included it both.
Hyderabad-based Dr Reddy’s Laboratories can be launching its generic model of the Merck drug, known as Molflu (molnupiravir), from early subsequent week which can be priced at ₹35 per capsule.
With 10 capsules per strip, the whole course of 40 capsules over 5 days would value ₹1,400, making it among the many most inexpensive therapy choices obtainable to sufferers, it added. “Molflu is predicted to be obtainable from early subsequent week in pharmacies all through the nation with explicit give attention to states with excessive caseload of COVID-19,” the spokesperson famous.
The corporate solely final week acquired the emergency-use authorisation from the Medicine Controller Normal of India (DCGI) to fabricate and market oral antiviral drug Molnupiravir capsules 200 mg for the therapy of grownup sufferers with COVID-19 who’ve excessive danger of development of the illness together with hospitalisation or demise.